These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8751173)

  • 41. [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview].
    Steinhoff BJ
    Fortschr Neurol Psychiatr; 1994 Oct; 62(10):379-88. PubMed ID: 8001894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic drug monitoring of felbamate].
    Tribut O; Bentué-Ferrer D; Verdier MC;
    Therapie; 2010; 65(1):35-8. PubMed ID: 20205993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of new and established antiepileptic drugs.
    Leppik IE
    Epilepsia; 1998; 39 Suppl 5():2-6. PubMed ID: 9737436
    [No Abstract]   [Full Text] [Related]  

  • 44. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors.
    Rho JM; Donevan SD; Rogawski MA
    Ann Neurol; 1994 Feb; 35(2):229-34. PubMed ID: 8109904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Felbamate.
    Med Lett Drugs Ther; 1993 Nov; 35(910):107-9. PubMed ID: 8232064
    [No Abstract]   [Full Text] [Related]  

  • 46. Felbamate in the treatment of partial-onset seizures.
    Bourgeois BF
    Epilepsia; 1994; 35 Suppl 5():S58-61. PubMed ID: 8039474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of felbamate in therapy for partial epilepsy in children.
    Carmant L; Holmes GL; Sawyer S; Rifai N; Anderson J; Mikati MA
    J Pediatr; 1994 Sep; 125(3):481-6. PubMed ID: 8071763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight loss in patients taking felbamate.
    Bergen DC; Ristanovic RK; Waicosky K; Kanner A; Hoeppner TJ
    Clin Neuropharmacol; 1995 Feb; 18(1):23-7. PubMed ID: 8665531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Re: Mazarati et al. "...clinically available [antiepileptic drug] with a moderate affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor".
    Rogawski MA; Wasterlain CG; Mazarati AM
    Epilepsia; 2000 Jul; 41(7):918-9. PubMed ID: 10897169
    [No Abstract]   [Full Text] [Related]  

  • 50. Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group.
    Avanzini G; Canger R; Dalla Bernardina B; Vigevano F
    Epilepsy Res; 1996 Nov; 25(3):249-55. PubMed ID: 8956923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome.
    Siegel H; Kelley K; Stertz B; Reeves-Tyer P; Flamini R; Malow B; Gaillard WD; Ko D; Theodore WH
    Epilepsy Res; 1999 Apr; 34(2-3):91-7. PubMed ID: 10210023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat.
    Sofia RD; Gordon R; Gels M; Diamantis W
    Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):335-41. PubMed ID: 8480078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
    Patsalos PN; Sander JW
    Drug Saf; 1994 Jul; 11(1):37-67. PubMed ID: 7917080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice.
    Gasior M; Swiader M; Przybyłko M; Borowicz K; Turski WA; Kleinrok Z; Czuczwar SJ
    Eur J Pharmacol; 1998 Jul; 352(2-3):207-14. PubMed ID: 9716356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroprotective effect of felbamate after kainic acid-induced status epilepticus.
    Chronopoulos A; Stafstrom C; Thurber S; Hyde P; Mikati M; Holmes GL
    Epilepsia; 1993; 34(2):359-66. PubMed ID: 8453945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective antagonism of the anticonvulsant effects of felbamate by glycine.
    Coffin V; Cohen-Williams M; Barnett A
    Eur J Pharmacol; 1994 Apr; 256(2):R9-10. PubMed ID: 8050461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in the pharmacotherapy of epilepsy.
    Ramsay RE
    Epilepsia; 1993; 34 Suppl 5():S9-16. PubMed ID: 8339715
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of felbamate and diazepam against maximal electroshock seizures and chemoconvulsants in mice.
    Gordon R; Gels M; Diamantis W; Sofia RD
    Pharmacol Biochem Behav; 1991 Sep; 40(1):109-13. PubMed ID: 1664105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Felbamate monotherapy: implications for antiepileptic drug development.
    Theodore WH; Albert P; Stertz B; Malow B; Ko D; White S; Flamini R; Ketter T
    Epilepsia; 1995 Nov; 36(11):1105-10. PubMed ID: 7588454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
    De Sarro G; Ongini E; Bertorelli R; Aguglia U; De Sarro A
    Eur J Pharmacol; 1994 Sep; 262(1-2):11-9. PubMed ID: 7529182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.